Fédération des Centres Mémoire, Lyon, France.
Société Française de Neurologie, Paris, France.
J Alzheimers Dis. 2018;66(2):425-427. doi: 10.3233/JAD-180843.
The French Minister of Health published a decree on May 29th of 2018 removing the drugs used to fight against symptoms due to Alzheimer's disease (donepezil, rivastigmine, galantamine, memantine) from the list of available reimbursed drugs. This follows the advice delivered by the High Authority for Health in 2016 and 2018 stating an "insufficient medical benefit and dangerousness because of significant side effects". The main French scientific and medical societies and professional associations want to state here their deep disagreement regarding this unfair decision. The evidence-based medicine related to these drugs reaches a high level in literature, whereas the clinical relevance of these treatments must be considered with co-prescription of psychosocial interventions and related approaches. As no serious pharmacovigilance signal has been provided by health authorities, the ratio of benefits/risks favors these drugs.
2018 年 5 月 29 日，法国卫生部长发布一项法令，将用于治疗阿尔茨海默病症状的药物（多奈哌齐、利伐斯的明、加兰他敏、美金刚）从可报销药物清单中删除。这是继 2016 年和 2018 年法国高级卫生署提出“医疗获益不足且因严重副作用而具有危险性”的建议后采取的措施。法国主要的科学和医学协会以及专业协会希望在此声明，他们对这一不公平的决定深表不满。这些药物的循证医学在文献中达到了很高的水平，而这些治疗方法的临床相关性必须与心理社会干预和相关方法的共同处方一起考虑。由于卫生当局没有提供严重的药物警戒信号，因此药物的获益/风险比有利于这些药物。
